Pharmaceutical firms seek independent deals to avoid Trump price controls
Drug companies not included in initial White House pricing agreements are pushing for their own deals. They hope to avoid new Medicare price-setting rules.
Insights:
Pharmaceutical companies that were not included in the initial drug-pricing agreements announced by President Donald Trump are currently seeking to negotiate their own individual deals with the White House and the Centers for Medicare & Medicaid Services (CMS). These manufacturers are aiming to secure favorable terms to avoid potential tariffs and to limit their exposure to new Medicare price-setting pilot programs. This movement in the US 
US follows a series of directive letters from the Trump administration that resulted in agreements with 16 large drugmakers, leaving a significant portion of the industry without formal arrangements.
US follows a series of directive letters from the Trump administration that resulted in agreements with 16 large drugmakers, leaving a significant portion of the industry without formal arrangements.
